Mucosal-associated invariant T cells are a profibrogenic immune cell population in the liver

Pushpa Hegde(Inserm), Emmanuel Weiss(Inserm), Valérie Paradis(Inserm), JingHong Wan(Inserm), Morgane Mabire(Inserm), Sukriti Sukriti(Inserm), Pierre‐Emmanuel Rautou(Hôpital Beaujon), Miguel Albuquerque(Inserm), Olivia Picq(Inserm), Abhishak Chandra Gupta(Inserm), Gladys Ferrere(Inserm), Hélène Gilgenkrantz(Inserm), Badr Kiaf(Centre National de la Recherche Scientifique), Amine Toubal(Centre National de la Recherche Scientifique), Lucie Beaudoin(Centre National de la Recherche Scientifique), Philippe Lettéron(Inserm), Richard Moreau(Inserm), Agnès Lehuen(Centre National de la Recherche Scientifique), Sophie Lotersztajn(Inserm)
Nature Communications
May 25, 2018
Cited by 223Open Access
Full Text

Abstract

Liver fibrosis is the common response to chronic liver injury, and leads to cirrhosis and its complications. Persistent inflammation is a driving force of liver fibrosis progression. Mucosal-associated invariant T (MAIT) cells are non-conventional T cells that display altered functions during chronic inflammatory diseases. Here, we show that circulating MAIT cells are reduced in patients with alcoholic or non-alcoholic fatty liver disease-related cirrhosis while they accumulate in liver fibrotic septa. Using two models of chronic liver injury, we demonstrate that MAIT cell-enriched mice show increased liver fibrosis and accumulation of hepatic fibrogenic cells, whereas MAIT cell-deficient mice are resistant. Co-culture experiments indicate that MAIT cells enhance the proinflammatory properties of monocyte-derived macrophages, and promote mitogenic and proinflammatory functions of fibrogenic cells, via distinct mechanisms. Our results highlight the profibrogenic functions of MAIT cells and suggest that targeting MAIT cells may constitute an attractive antifibrogenic strategy during chronic liver injury.


Related Papers